The FDA and its new commissioner must follow the science

In an op-ed for The Hill, Susan F. Wood explains that anti-abortion groups are targeting FDA commissioner nominee Dr. Robert Califf over the abortion drug mifepristone. "At this pivotal moment for the FDA, and amidst an ongoing public health emergency that already curtails access to health care, the vote for the next FDA commissioner must be based on their ability to uphold scientific decision-making," she writes.